Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy

被引：14

作者：

Hashimoto, Masao ^{[1
,2
]}

Ramalingam, Suresh S. ^{[3
]}

Ahmed, Ra fi ^{[1
,2
,3
]}

机构：

[1] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA

[2] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA

[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

来源：

TRENDS IN CANCER | 2024年 / 10卷 / 04期

基金：

美国国家卫生研究院;

关键词：

CHRONIC INFECTION; IMMUNE EVASION; IL-2; RECEPTOR; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTES; EXHAUSTION; BIOLOGY; TUMORS; GROWTH;

D O I：

10.1016/j.trecan.2023.11.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There is considerable interest in developing more effective programmed cell death (PD)-1 combination therapies against cancer. One major obstacle to these efforts is a dysfunctional/exhausted state of CD8 T cells, which PD-1 monotherapy is not able to overcome. Recent studies have highlighted that PD-1+ T cell factor (TCF)-1+ stem-like CD8 T cells are not fate locked into the exhaustion program and their differentiation trajectory can be changed by interleukin (IL)-2 signals. Modifying the CD8 T cell exhaustion program and generating better effectors from stem-like CD8 T cells by IL-2 form the fundamental immunological basis for combining IL-2 with PD-1 therapy. Many versions of IL-2-based products are being tested and each product should be carefully evaluated for its ability to modulate dysfunctional states of anti-tumor CD8 T cells.

引用

页码：332 / 346

页数：15

共 77 条

[1] TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection [J].

Alfei, Francesca ;

Kanev, Kristiyan ;

Hofmann, Maike ;

Wu, Ming ;

Ghoneim, Hazem E. ;

Roelli, Patrick ;

Utzschneider, Daniel T. ;

von Hoesslin, Madlaina ;

Cullen, Jolie G. ;

Fan, Yiping ;

Eisenberg, Vasyl ;

Wohlleber, Dirk ;

Steiger, Katja ;

Merkler, Doron ;

Delorenzi, Mauro ;

Knolle, Percy A. ;

Cohen, Cyrille J. ;

Thimme, Robert ;

Youngblood, Benjamin ;

Zehn, Dietmar .

NATURE, 2019, 571 (7764) :265-+

[2] Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance [J].

Bagchi, Sreya ;

Yuan, Robert ;

Engleman, Edgar G. .

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021, 2021, 16 :223-249

[3] Restoring function in exhausted CD8 T cells during chronic viral infection [J].

Barber, DL ;

Wherry, EJ ;

Masopust, D ;

Zhu, BG ;

Allison, JP ;

Sharpe, AH ;

Freeman, GJ ;

Ahmed, R .

NATURE, 2006, 439 (7077) :682-687

[4] An essential role for the IL-2 receptor in Treg cell function [J].

Chinen, Takatoshi ;

Kannan, Arun K. ;

Levine, Andrew G. ;

Fan, Xiying ;

Klein, Ulf ;

Zheng, Ye ;

Gasteiger, Georg ;

Feng, Yongqiang ;

Fontenot, Jason D. ;

Rudensky, Alexander Y. .

NATURE IMMUNOLOGY, 2016, 17 (11) :1322-1333

[5] A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response [J].

Connolly, Kelli A. ;

Kuchroo, Manik ;

Venkat, Aarthi ;

Khatun, Achia ;

Wang, Jiawei ;

William, Ivana ;

Hornick, Noah, I ;

Fitzgerald, Brittany L. ;

Damo, Martina ;

Kasmani, Moujtaba Y. ;

Cui, Can ;

Fagerberg, Eric ;

Monroy, Isabel ;

Hutchins, Amanda ;

Cheung, Julie F. ;

Foster, Gena G. ;

Mariuzza, Dylan L. ;

Nader, Mursal ;

Zhao, Hongyu ;

Cui, Weiguo ;

Krishnaswamy, Smita ;

Joshi, Nikhil S. .

SCIENCE IMMUNOLOGY, 2021, 6 (64)

[6] PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells [J].

Deak, Laura Codarri ;

Nicolini, Valeria ;

Hashimoto, Masao ;

Karagianni, Maria ;

Schwalie, Petra C. ;

Lauener, Laura ;

Varypataki, Eleni Maria ;

Richard, Marine ;

Bommer, Esther ;

Sam, Johannes ;

Joller, Stefanie ;

Perro, Mario ;

Cremasco, Floriana ;

Kunz, Leo ;

Yanguez, Emilio ;

Husser, Tamara ;

Schlenker, Ramona ;

Mariani, Marisa ;

Tosevski, Vinko ;

Herter, Sylvia ;

Bacac, Marina ;

Waldhauer, Inja ;

Colombetti, Sara ;

Gueripel, Xavier ;

Wullschleger, Stephan ;

Tichet, Melanie ;

Hanahan, Douglas ;

Kissick, Haydn T. ;

Leclair, Stephane ;

Freimoser-Grundschober, Anne ;

Seeber, Stefan ;

Teichgraber, Volker ;

Ahmed, Rafi ;

Klein, Christian ;

Umana, Pablo .

NATURE, 2022, 610 (7930) :161-+

[7]

Deckers J, 2023, NAT REV BIOENG, V1, P286, DOI 10.1038/s44222-023-00030-y

[8] Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results [J].

Diab, Adi ;

Gogas, Helen ;

Sandhu, Shahneen ;

Long, Georgina V. ;

Ascierto, Paolo A. ;

Larkin, James ;

Sznol, Mario ;

Franke, Fabio ;

Ciuleanu, Tudor E. ;

Pereira, Caio ;

Munoz Couselo, Eva ;

Bronzon Damian, Fernanda ;

Schenker, Michael ;

Perfetti, Aldo ;

Lebbe, Celeste ;

Quereux, Gaelle ;

Meier, Friedegund ;

Curti, Brendan D. ;

Rojas, Carlos ;

Arriaga, Yull ;

Yang, Haisu ;

Zhou, Ming ;

Ravimohan, Shruthi ;

Statkevich, Paul ;

Tagliaferri, Mary A. ;

Khushalani, Nikhil I. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (30) :4756-+

[9] Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer [J].

Eberhardt, Christiane S. ;

Kissick, Haydn T. ;

Patel, Mihir R. ;

Cardenas, Maria A. ;

Prokhnevska, Nataliya ;

Obeng, Rebecca C. ;

Nasti, Tahseen H. ;

Griffith, Christopher C. ;

Im, Se Jin ;

Wang, Xu ;

Shin, Dong M. ;

Carrington, Mary ;

Chen, Zhuo G. ;

Sidney, John ;

Sette, Alessandro ;

Saba, Nabil F. ;

Wieland, Andreas ;

Ahmed, Rafi .

NATURE, 2021, 597 (7875) :279-+

[10] Identification of a protein fragment of interleukin 2 responsible for vasopermeability [J].

Epstein, AL ;

Mizokami, MM ;

Li, JL ;

Hu, PS ;

Khawli, LA .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (10) :741-749

← 1 2 3 4 5 6 7 8 →